International Medical Case Reports Journal (Kinderlehrer D.) 3.3.23, published “The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.” The report illustrates the case of an immunocompetent male patient with serologically positive neuropsychiatric Lyme disease who had not been tolerating antimicrobial or psychotropic treatments.
Search Results for: treatment
About LymeAid 4 Kids (LA4K) – The Lyme Disease Association started LA4K fund in 2003 and has distributed monies for children all over the U.S.since 2004, Developed with the help […]
To help increase awareness and education throughout the country, LDA believes it is essential to work with and assist other Lyme organizations. PURPOSES INCLUDE: Publications (include Lyme Times, The Basics, […]
The journal JAMA (Rubin, R.) 6.8.22 published “From Positive to Negative to Positive Again—The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid,” the incidence of COVID rebound cases in patients who had taken Pfizer’s antiviral nirmatrelvir/ritonavir, aka, Paxlovid. In late spring of 2022, rebound cases were being reported in medical literature and on social media, urging the US Centers for Disease Control and Prevention’s (CDC) Health Alert Network to issue a health advisory on May 24, 2022.
Annals of Geriatric Medicine and Research (Sanchini, C., et al.) 2.6.23, published “A case of reversible dementia? Dementia vs delirium in Lyme disease.” The report details the case of a 75-year-old man who was admitted to the Alzheimer’s Disease Care Unit of the Institute Golgi, Italy.
Lyme Disease Association Inc (LDA) Board of Directors Member Jeannine Phillips attended the first virtual meeting of ICUE, the CDC Foundation’s new infectious disease-based initiative, February 8, 2023, which includes Lyme disease. About 40 patient advocacy and community-based organizations from different health conditions were represented in the initial endeavor. Meeting report from Jeannine (picture) follows.